Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M7,679Revenue $M1,165Net Margin (%)5.6Altman Z-Score3.6
Enterprise Value $M7,679EPS $0.8Operating Margin %10.5Piotroski F-Score5
P/E(ttm)126Beneish M-Score-2.5Pre-tax Margin (%)5.7Higher ROA y-yY
Price/Book5.010-y EBITDA Growth Rate %--Quick Ratio3.3Cash flow > EarningsY
Price/Sales7.25-y EBITDA Growth Rate %-24.1Current Ratio3.5Lower Leverage y-yY
Price/Free Cash Flow68.4y-y EBITDA Growth Rate %115ROA % (ttm)2.1Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)4.5Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M76.3ROIC % (ttm)4.8Gross Margin Increase y-yN

Gurus Latest Trades with CBST

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
CBSTPrem Watsa 2014-12-31 Buy 0.13%$60.05 - $100.71
($77.67)
$ 101.9431%New holding20,200
CBSTMario Gabelli 2014-12-31 Buy 0.12%$60.05 - $100.71
($77.67)
$ 101.9431%New holding236,700
CBSTFirst Eagle Investment 2014-12-31 Buy $60.05 - $100.71
($77.67)
$ 101.9431%New holding20,000
CBSTKen Fisher 2014-12-31 Reduce$60.05 - $100.71
($77.67)
$ 101.9431%Reduce 93.82%2,150
CBSTVanguard Health Care Fund 2014-09-30 Add0.09%$60.5 - $70.58
($65.63)
$ 101.9455%Add 34.74%1,977,342
CBSTGeorge Soros 2014-06-30 Sold Out -0.04%$61.66 - $74.27
($67.99)
$ 101.9450%Sold Out0
CBSTKen Fisher 2014-06-30 Buy 0.01%$61.66 - $74.27
($67.99)
$ 101.9450%New holding36,450
CBSTGeorge Soros 2014-03-31 Reduce-0.06%$67.2 - $81.23
($74.39)
$ 101.9437%Reduce 65.40%50,000
CBSTJoel Greenblatt 2013-12-31 Sold Out -0.05%$61.59 - $70.76
($64.66)
$ 101.9458%Sold Out0
CBSTMichael Price 2013-09-30 Sold Out -1.2%$51.58 - $66.54
($60.56)
$ 101.9468%Sold Out0
CBSTGeorge Soros 2013-06-30 Buy 0.09%$44.66 - $56.11
($49.15)
$ 101.94107%New holding175,000
CBSTJoel Greenblatt 2013-03-31 Reduce-0.18%$40.78 - $48.06
($44.18)
$ 101.94131%Reduce 72.24%28,134
CBSTJoel Greenblatt 2012-12-31 Buy 0.25%$39.17 - $48.63
($43.07)
$ 101.94137%New holding101,334
CBSTJoel Greenblatt 2012-09-30 Sold Out -0.12%$37.91 - $49.83
($43.89)
$ 101.94132%Sold Out0
CBSTJoel Greenblatt 2012-06-30 Add0.04%$38.38 - $44.07
($40.88)
$ 101.94149%Add 49.02%41,492
CBSTJoel Greenblatt 2012-03-31 Reduce-0.17%$38.77 - $44.72
($38.64)
$ 101.94164%Reduce 55.29%27,844
CBSTGeorge Soros 2012-03-31 Sold Out -0.09%$38.77 - $44.72
($38.64)
$ 101.94164%Sold Out0
CBSTJoel Greenblatt 2011-12-31 Reduce-0.42%$34.05 - $40.38
($37.51)
$ 101.94172%Reduce 53.85%62,273
CBSTGeorge Soros 2011-12-31 Reduce-0.03%$34.05 - $40.38
($37.51)
$ 101.94172%Reduce 50.00%50,000
CBSTMichael Price 2011-09-30 Add0.49%$29.59 - $36.93
($34.13)
$ 101.94199%Add 73.57%182,500
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

CBST is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


CBST: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
GILMAN STEVEN CEVP & Chief Scientific Officer 2014-10-01Sell48,125$65.3955.9 view
STEA GREGORYSVP, Commercial Operations 2014-08-19Sell38,326$65.8854.74 view
Hutson Nancy JDirector 2014-08-18Sell9,000$6556.83 view
PEREZ ROBERT JPresident & COO 2014-08-18Sell1,003$63.6860.08 view
TOMSICEK MICHAEL JOHNSVP & CFO 2014-08-18Sell409$63.6860.08 view
GILMAN STEVEN CEVP & Chief Scientific Officer 2014-07-28Sell40,625$61.5765.57 view
STEA GREGORYSVP, Commercial Operations 2014-05-15Sell875$67.551.02 view
PEREZ ROBERT JPresident & COO 2014-05-15Sell1,518$67.551.02 view
GILMAN STEVEN CEVP & Chief Scientific Officer 2014-05-15Sell16,340$67.8250.31 view
BONNEY MICHAEL WCEO 2014-05-15Sell3,036$67.551.02 view

Quarterly/Annual Reports about CBST:

    News about CBST:

    Articles On GuruFocus.com
    Mario Gabelli's Top 5 Stock Picks Mar 30 2015 
    Prem Watsa Buys 2 and Sells 1 Stock in Fourth Quarter Feb 16 2015 
    Mario Gabelli's Top 5 New Stock Buys of Q4 Feb 05 2015 
    Gabelli's Q4 Picks Include Acquisition Targets Feb 06 2015 
    Pharmaceutical Giant Merck Buys Cubist Pharma Dec 09 2014 
    Forest Laboratories Is an Option for Wealthy Investors Who Could Afford to Pay a High Premium Apr 23 2014 
    Michael Price’s Top Sells – 11 Gurus Exit SFD Nov 19 2013 
    Magic Formula Formulator Joel Greenblatt’s Top 5 New Stock Picks Feb 14 2013 
    5 Healthcare Stocks to Consider in 2012 Mar 21 2012 
    Cubist Pharmaceutical - Acutely Aware May 09 2010 

    More From Other Websites
    Everything you need to know about the $8.4B acquisition of Synageva May 06 2015
    Superbugs Turn Big Pharma, Gov't Focus To Antibiotics Apr 09 2015
    Mario Gabelli's Top 5 Stock Picks Mar 31 2015
    Farallon Capital Starts New Position in Cubist Pharmaceuticals Mar 20 2015
    Tetraphase looks to double its cash with stock offering Mar 10 2015
    Layoffs at Cubist come amid a steady flow of senior execs out of Merck Mar 06 2015
    Elliott Management exits position in Covidien Mar 04 2015
    Elliott Management starts new position in Cubist Pharmaceuticals Mar 02 2015
    Prem Watsa's Stock Buys and Sells of Q4 Feb 17 2015
    Dana Holding Set to Join the S&P MidCap 400 Jan 20 2015
    Cubist Announces Withdrawal of Listing of CVRs (CBSTZ) from NASDAQ Global Select Market Jan 13 2015
    Teixobactin And iChip Promise Hope Against Antibiotic Resistance Jan 08 2015
    Cramer's Mad Dash: Pharma movers Dec 24 2014
    Approval of new antibiotic by Cubist to help in $100 trillion global fight Dec 22 2014
    FDA Approves Second Cubist Antibiotic Of 2014 Dec 19 2014
    Cubist Announces FDA Approval of New Antibiotic ZERBAXA™ (Ceftolozane/Tazobactam) for Complicated... Dec 19 2014
    FDA approves Cubists' drug for antibiotic-resistant bacteria Dec 19 2014
    Merck Begins Tender Offer to Acquire Cubist Dec 19 2014
    $100 trillion Superbugs threat Dec 18 2014
    Tetraphase Jumps As 'Superbug' Drug Scores In Trial Dec 18 2014

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK